`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`AMERIGEN PHARMACEUTICALS LIMITED
`
`Petitioner,
`
`V.
`
`JANSSEN ONCOLOGY, INC.
`Patent Owner.
`
`Case IPR2016—00286
`
`Patent 8,822,438 B2
`
`DECLARATION OF S. ISAAC OLSON IN
`
`SUPPORT OF MOTION TO APPEAR PRO HAC VICE
`
`JANSSEN EXHIBIT 2027
`
`Ameri en v. Janssen lPR2016-00286
`
`JANSSEN EXHIBIT 2027
`Amerigen v. Janssen IPR2016-00286
`
`
`
`IPR2016—0O286
`
`Patent No. 8,822,438
`
`I, S. Isaac Olson, declare as follows:
`
`1.
`
`I am counsel in the New York Office of Sidley Austin LLP.
`
`I have
`
`personal knowledge of the facts set forth in this declaration and, if called as a
`
`witness, could and would testify competently under oath.
`
`2.
`
`I am a member in good standing of the State Bar of New York (Bar
`
`No. 4625190).
`
`3.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`4.
`
`None of my applications for admission to practice before any court or
`
`administrative body have ever been denied.
`
`5.
`
`I have not been sanctioned nor have I had a contempt citation imposed
`
`on me by any court or administrative body.
`
`6.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trial set forth in part 42 of 37 C.F.R.
`
`7.
`
`I acknowledge and agree that I will be subject to the USPTO Rules of
`
`Professional Conduct set forth in 37 C.F.R. § 11.101 et. seq. and disciplinary
`
`jurisdiction under 37 C.F.R. § 1l.l9(a).
`
`8.
`
`I have not applied to appear pro hac vice before the Patent Trial and
`
`Appeal Board in the last three years.
`
`
`
`IPR2O l 6—00286
`
`Patent No. 8,822,438
`
`9.
`
`I have been a practicing attorney for almost nine years and have been
`
`involved in numerous patent cases. I am presently counsel for Patent Owner
`
`Janssen Oncology, Inc. in two pending patent litigationsl involving the patent
`
`under review in this proceeding, U.S. Patent No. 8,822,438 (the “’438 patent”). As
`
`part of these litigations, I have studied and analyzed the ‘438 patent and have
`
`become very familiar with its subject matter. I have also gained familiarity with
`
`certain prior art (including prior art asserted in this IPR proceeding), conception
`
`and reduction to practice of the inventions claimed in the ‘438 patent, and other
`
`relevant issues, including claim construction of various claim terms.
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`Executed on 7A\LJ§-.354’
`
`(Ci
`
`, 2016 in New York, New York
`
`By:
`
`. Isaac Olson
`
`1 BTG Int 7 Ltd., er al., v. Actavis Labs. FL, Inc., et al., C.A. No. 2:l5—cV—
`
`O5909—KM-JBC (D.N.J.) and Janssen Biotech, Inc., et al., v. Mylan Pharm. Ina, er
`
`al., C.A. No. 1:l5—cv-O0l30—IMK(N.D. w. Va.).